Abstract
In this communication, we report the discovery of 1S (apremilast), a novel potent and orally active phosphodiesterase 4 (PDE4) and tumor necrosis factor-alpha inhibitor. The optimization of previously reported 3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-3-(3,4-dimethoxyphenyl)propionic acid PDE4 inhibitors led to this series of sulfone analogues. Evaluation of the structure-activity relationship of substitutions on the phthalimide group led to the discovery of an acetylamino analogue 1S, which is currently in clinical trials.
MeSH terms
-
Administration, Oral
-
Animals
-
Drug Discovery*
-
Humans
-
Phosphodiesterase 4 Inhibitors*
-
Phosphodiesterase Inhibitors / administration & dosage
-
Phosphodiesterase Inhibitors / chemistry
-
Phosphodiesterase Inhibitors / pharmacology*
-
Rats
-
Stereoisomerism
-
Structure-Activity Relationship
-
Thalidomide / administration & dosage
-
Thalidomide / analogs & derivatives*
-
Thalidomide / chemistry
-
Thalidomide / pharmacology
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Phosphodiesterase 4 Inhibitors
-
Phosphodiesterase Inhibitors
-
Tumor Necrosis Factor-alpha
-
Thalidomide
-
apremilast